Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 7.43%-374K | 19.17%-586K | -36.39%-416K | 30.23%-2.06M | 9.24%-629K | 29.98%-404K | 33.85%-725K | 48.39%-305K | -87.15%-2.96M | -178.31%-693K |
| Net income from continuing operations | -1,771.94%-2.6M | 127.51%482K | 49.12%-893K | -105.72%-7.33M | -1,184.12%-3.69M | 94.24%-139K | -826.98%-1.75M | -34.90%-1.76M | 55.02%-3.56M | 127.76%340K |
| Operating gains losses | 136.77%328K | -1,700.76%-2.1M | -196.51%-830K | 333.44%2.29M | 322.44%2.19M | -214.80%-892K | 135.50%131K | 312.87%860K | -162.13%-981K | 50.38%-985K |
| Depreciation and amortization | 16.67%14K | 8.33%13K | 18.18%13K | 4.44%47K | 9.09%12K | 9.09%12K | 0.00%12K | 0.00%11K | 0.00%45K | 0.00%11K |
| Unrealized gains and losses of investment securities | -28.57%5K | 100.00%4K | -325.00%-17K | ---- | ---- | 250.00%7K | 200.00%2K | 33.33%-4K | ---- | ---- |
| Remuneration paid in stock | 335.92%880K | 0.86%117K | 119.33%87K | 50.36%-619K | 109.77%88K | -549.40%-373K | 113.91%116K | -211.11%-450K | -209.39%-1.25M | -157.54%-901K |
| Other non cashItems | 7.34%951K | -4.61%848K | 7.57%980K | 12.13%3.6M | 27.63%910K | 7.39%886K | 8.95%889K | 6.80%911K | -0.06%3.21M | -10.88%713K |
| Change In working capital | -47.37%50K | 138.21%47K | 100.00%244K | 89.21%-45K | -213.01%-139K | -31.65%95K | 76.79%-123K | 181.88%122K | -212.40%-417K | -62.73%123K |
| -Change in receivables | -31.71%-54K | 196.88%31K | -60.53%15K | -300.00%-16K | -54.76%19K | -133.06%-41K | 79.75%-32K | --38K | 129.63%8K | 282.61%42K |
| -Change in payables and accrued expense | -23.53%104K | 117.58%16K | 172.62%229K | 93.18%-29K | -295.06%-158K | 806.67%136K | 75.54%-91K | 156.38%84K | -206.78%-425K | -77.05%81K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 7.43%-374K | 19.17%-586K | -36.39%-416K | 30.23%-2.06M | 9.24%-629K | 29.98%-404K | 33.85%-725K | 48.39%-305K | -87.15%-2.96M | -178.31%-693K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -6.98%-92K | -3.49%-89K | 0 | -8.86%-86K | -86K | ||||
| Capital expenditure reported | ---- | ---- | ---- | -1.18%-86K | ---- | ---- | ---- | ---- | -7.59%-85K | ---- |
| Net PPE purchase and sale | --0 | ---- | ---- | -500.00%-6K | -200.00%-3K | --0 | ---- | ---- | ---1K | ---1K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | ---- | ---- | -6.98%-92K | -3.49%-89K | --0 | ---- | ---- | -8.86%-86K | ---86K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 4,035.71%1.1M | -47.53%626K | -6.04%-158K | -29.66%2.57M | 2,974.07%1.55M | -86.67%-28K | 8,621.43%1.19M | -103.99%-149K | 168.06%3.65M | -117.20%-54K |
| Net issuance payments of debt | 7,985.71%1.1M | 5,046.15%643K | -7.69%-14K | 7.55%-49K | 35.71%-9K | -7.69%-14K | 0.00%-13K | 0.00%-13K | -103.36%-53K | -104.24%-14K |
| Net common stock issuance | --0 | ---- | ---- | -23.49%3.07M | --1.78M | --0 | --1.3M | --0 | --4.02M | --0 |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Interest paid (cash flow from financing activities) | 0.00%-2K | 0.00%-1K | 0.00%-2K | -16.67%-7K | -100.00%-2K | 0.00%-2K | 0.00%-1K | 0.00%-2K | -20.00%-6K | 0.00%-1K |
| Net other financing activities | --0 | 81.82%-16K | -5.97%-142K | -46.89%-448K | -448.72%-214K | ---12K | ---88K | 49.62%-134K | -45.24%-305K | -160.00%-39K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 4,035.71%1.1M | -47.53%626K | -6.04%-158K | -29.66%2.57M | 2,974.07%1.55M | -86.67%-28K | 8,621.43%1.19M | -103.99%-149K | 168.06%3.65M | -117.20%-54K |
| Net cash flow | ||||||||||
| Beginning cash position | -29.77%434K | 156.52%413K | 62.72%1M | 2,470.83%617K | -88.02%174K | -70.61%618K | -94.89%161K | 2,470.83%617K | -92.90%24K | 1,649.40%1.45M |
| Current changes in cash | 268.52%728K | -91.40%40K | -26.43%-574K | -32.07%413K | 200.12%834K | 27.03%-432K | 141.89%465K | -114.44%-454K | 304.71%608K | -5,850.00%-833K |
| Effect of exchange rate changes | 0.00%-12K | -137.50%-19K | -750.00%-17K | -73.33%-26K | -100.00%-4K | 79.66%-12K | -112.70%-8K | 88.24%-2K | 11.76%-15K | 95.56%-2K |
| End cash Position | 560.92%1.15M | -29.77%434K | 156.52%413K | 62.72%1M | 62.72%1M | -88.02%174K | -70.61%618K | -94.89%161K | 2,470.83%617K | 2,470.83%617K |
| Free cash from | 7.43%-374K | 19.51%-586K | -36.39%-416K | 29.18%-2.16M | 7.83%-718K | 29.98%-404K | 33.58%-728K | 48.39%-305K | -83.42%-3.04M | -137.50%-779K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.